



Australian Clinical Labs Limited

ABN 94 645 711 128

Registered Office:

1868-1892 Dandenong Road

Clayton VIC 3168

Australia

clinicallabs.com.au

Tuesday, 21st May 2024

Trading Update

Australian Clinical Labs Limited (ASX: ACL) (ACL or the Company) reaffirms its guidance range announced on 28 February 2024 and anticipates the full year results based on trading to date will fall at the lower end of the underlying EBIT range previously provided of \$60m to \$65m. This is based on unaudited management accounts to 30 April 2024 and assumes market volumes continue at current trends.

– ENDS –

This announcement was authorised for release to the ASX by the ACL Board.

For further information regarding this announcement, please contact:

Investors

Eleanor Padman

Company Secretary

Email: epadman@padmanadvisory.com.au

Phone: +61 (0) 422 002 918

Media

Clive Mathieson, Sue Cato

Email: clive@catoandclive.com

cato@catoandclive.com

Phone: +61 (0) 411 888 425

+61 (0) 419 282 319

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.

